Stephany Veuger

Northumbria University

A significant focus of Stephany Veuger's research has been to evaluate DNA repair inhibitors as potential drugs to be used in combination with current therapies or as stand-alone therapies in cancer treatment. She has supported anticancer drug discovery projects by (1) evaluating drugs to exploit underlying molecular defects in a range of human cancers,(2) investigating interactive effects of proteins involved in sensing and responding to DNA damage,(3) developing and validating pharmacodynamic biomarkers for agents progressing to clinical trials.She has played a vital role in the drug development group at the Northern Cancer Centre. Her work evaluating agents progressing to clinical trials and developing biomarkers contributed to the successful introduction of PARP inhibitors into patients. She is interested in solid tumors (breast and prostate) and hematological malignancies. She currently collaborates with medicinal chemists to explore the underlying biological mechanisms of novel therapeutics alone and in combination with repair inhibitors.  

Seth Racey

Northumbria University

As a multi-disciplinary researcher, Dr. Racey has research outputs in molecular ecology, circadian clocks, orthopedic implants, and stem cells for regenerative medicine. His research recently focuses on using iron ion manipulation with novel metal chelators to treat cancers. He also has the background to recruit collaborators from disciplines that can inform cancer biology and bring novel perspectives. 

Gina Abdelaal

Northumbria University

Gina Abdelaal is a PhD student at Northumbria University supervised by Dr. Stephany Veuger. Her research project involves screening a panel of cell lines for their sensitivity to in-house synthesized novel iron chelator SK4 and determining the mechanism behind SK4 action. She is experienced in cell culture methodology. She has grown and screened ten different cell lines during her PhD and optimized various laboratory techniques related to the hallmarks of cancer (cell viability assays, flow cytometry, Western blotting, PCR, immunofluorescence, and proteomics). She is also a peer reviewer for STAR protocols and evaluates new methods papers for their clarity, content, and ease of reproducibility.